retatrutide ly3437943 clinical trial results Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

Yan J, et

It received FDA approval in 2022 for diabetes and 2023 for obesity

What does compounded GLP-1 cost at PlexusDx

Particularly noteworthy is that in patients with both type 2 diabetes and MASLD, after 24 weeks of treatment with a 10 mg dose of efinopegdutide, liver fat content reduced by 72.7%, a result that is superior to the 42.3% reduction achieved with a 1 mg dose of semaglutide, despite a similar overall weight loss being observed with the two interventions

This finding could pave the way for more targeted treatments that go beyond blood sugar management to directly address kidney deterioration and cardiovascular risks in diabetes